List of Angeliq drug patents

Angeliq is owned by Bayer Hlthcare.

Angeliq contains Drospirenone; Estradiol.

Angeliq has a total of 1 drug patent out of which 0 drug patents have expired.

Angeliq was authorised for market use on 28 September, 2005.

Angeliq is available in tablet;oral dosage forms.

The generics of Angeliq are possible to be released after 22 October, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(8 years from now)

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 28 September, 2005

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ANGELIQ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in